Han Jingjing, Geng Yan, Deng Xuerong, Zhang Zhuoli
Department of Geriatrics, Peking University First Hospital, Beijing, China.
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Clin Rheumatol. 2017 Aug;36(8):1721-1727. doi: 10.1007/s10067-017-3736-0. Epub 2017 Jun 22.
Ultrasonographic remission in addition to clinical remission is probably becoming a new target in the treatment of rheumatoid arthritis. The current study aimed to investigate the risk factors of flare in RA patients who achieved both clinical and ultrasonographic remission. RA patients fulfilled both clinical remission and ultrasonographic remissions were retrospectively enrolled in this study. Baseline clinical, laboratory, and ultrasonographic data were collected. Durations of clinical remission before enrollment and medication strategy during follow-up were recorded. Differences between the flare and the non-flare group were analyzed. Risk factors of flare were assessed with univariate and multivariate Cox proportional hazards models. One hundred and twenty-one RA patients were included. Forty-eight patients relapsed during a median follow-up period of 12.3 months. The flare group had higher percentage of females, shorter duration of clinical remission before enrollment, higher baseline ESR and DAS28 (ESR), and lower baseline gray scale score. Univariate Cox regression revealed female, short duration of remission, high DAS28 (ESR), and failure to achieve 2010 ACR/EULAR remission criteria were risk factors of flare. Furthermore, multivariate analysis showed short duration of remission was the only independent risk factor of flare (HR 0.93, 95% CI 0.88-0.98, P = 0.007). One more month in duration of remission led to a reduction in flare of 7.3%. Short duration of remission at baseline could be an independent risk factor of flare in RA patients who achieved both clinical and ultrasonographic remission, which implicates the significance of sustained remission in the prognosis of RA patients.
除临床缓解外,超声缓解可能正成为类风湿关节炎治疗的新目标。本研究旨在调查达到临床和超声缓解的类风湿关节炎(RA)患者病情复发的危险因素。本研究回顾性纳入了达到临床缓解和超声缓解的RA患者。收集了基线临床、实验室和超声数据。记录了入组前临床缓解的持续时间以及随访期间的用药策略。分析了病情复发组和未复发组之间的差异。采用单因素和多因素Cox比例风险模型评估病情复发的危险因素。共纳入121例RA患者。在中位随访期12.3个月期间,48例患者病情复发。病情复发组女性比例更高,入组前临床缓解持续时间更短,基线血沉(ESR)和疾病活动度评分28(DAS28,基于ESR)更高,而基线灰阶评分更低。单因素Cox回归显示,女性、缓解持续时间短、DAS28(ESR)高以及未达到2010年美国风湿病学会/欧洲抗风湿病联盟(ACR/EULAR)缓解标准是病情复发的危险因素。此外,多因素分析显示缓解持续时间短是病情复发的唯一独立危险因素(风险比[HR]0.93,95%置信区间[CI]0.88 - 0.98,P = 0.007)。缓解持续时间每增加1个月,病情复发风险降低7.3%。基线缓解持续时间短可能是达到临床和超声缓解的RA患者病情复发的独立危险因素,这提示持续缓解在RA患者预后中的重要性。